Skip to main content
aap Implantate AG logo

aap Implantate AG — Investor Relations & Filings

Ticker · AAQ1 ISIN · DE000A3H2101 LEI · 39120001TRQTQ01LPP57 F Manufacturing
Open in API
Filings indexed 854 across all filing types
Latest filing 2019-04-02 Earnings Release
Country DE Germany
Listing F AAQ1

About aap Implantate AG

https://www.aap.de/

aap Implantate AG is a medical technology company that operates as a pure player in the field of traumatology. The company develops, manufactures, and markets implants for the treatment of bone fractures. Its core product is the LOQTEQ® system, a comprehensive portfolio of anatomical plates and screws featuring a patented technology that combines fracture compression with angle-stable locking. This titanium-based system is designed to cover a broad spectrum of indications in upper and lower extremity trauma surgery. In addition to its established product line, aap is developing next-generation platform technologies, including antibacterial silver-coated implants to reduce infection risk and resorbable magnesium implants intended to eliminate the need for secondary removal surgeries.

Recent filings

Filing Released Lang Actions
aap: Good start to the year with 25% sales growth in Q1/2019; double-digit growth rates in all regions
Earnings Release Classification · 100% confidence The document is a news release disseminated via DGAP announcing preliminary sales figures for the first quarter (Q1/2019). It highlights key financial metrics (sales growth, EBITDA forecast adjustment) but explicitly states that the figures are preliminary and that the final figures will be published later (on May 13, 2019). This structure—an immediate announcement of key, unaudited results—is characteristic of an Earnings Release (ER). It is not the comprehensive Annual Report (10-K) or the detailed Interim Report (IR), but rather the initial highlight release. Q1 2019
2019-04-02 English
aap Implantate AG: Sales in Q1/2019 with EUR 3.5 million by EUR 0.5 million above the guidance
Earnings Release Classification · 100% confidence The document is a short announcement dated April 2, 2019, titled 'aap Implantate AG: Sales in Q1/2019 with EUR 3.5 million by EUR 0.5 million above the guidance'. It discloses preliminary results for Q1/2019, specifically sales figures and revised EBITDA expectations for the quarter, while maintaining guidance for the full year 2019. This content structure—a brief, immediate release of key preliminary financial figures ahead of a full report—is characteristic of an Earnings Release (ER). Although it mentions a subsequent press release for further details, the core content here is the initial earnings highlight, not just an announcement of a report's publication (RPA/RNS). Q1 2019
2019-04-02 English
aap Implantate AG / Silver coating technology: Further progress on the way to the targeted market approval - global orthopaedic companies remain keenly interested
Regulatory Filings Classification · 100% confidence The document is a news release dated March 28, 2019, disseminated via DGAP, which is a service often used for regulatory announcements in Germany. The content discusses ongoing business developments, regulatory progress (submission to BfArM for clinical study), and commercial discussions (partnerships, licensing deals) related to their silver coating technology. It is not a formal financial report (like 10-K or IR), an earnings release (ER), or a specific shareholder document (like DEF 14A or DVA). Since it is a general corporate update disseminated through a regulatory news service (DGAP) that doesn't fit neatly into the more specific categories like M&A (TAR) or Capital Change (CAP), it best fits the general Regulatory Filings/News category, which is RNS in this schema, serving as a broad announcement mechanism.
2019-03-28 English
aap Implantate AG: Postponement of publication of annual accounts 2018
Report Publication Announcement Classification · 99% confidence The document is a short news release dated March 12, 2019, titled "aap Implantate AG: Postponement of publication of annual accounts 2018". It explicitly states that the company has decided to postpone the publication of its annual financial statements 2018 (HGB) and consolidated financial statements 2018 (IFRS) to April 30, 2019. This is an announcement *about* a future report (the Annual Report/10-K), not the report itself. Given its nature as a regulatory announcement concerning a delay in financial reporting, and applying the 'MENU VS MEAL' rule (it announces the report rather than being the report), it fits best as a general Regulatory Filing (RNS) or potentially a Report Publication Announcement (RPA). Since it is a formal announcement disseminated via DGAP regarding a change in reporting schedule, RNS is the most appropriate general regulatory fallback, although RPA is also plausible. I will select RNS as it is a broad regulatory update.
2019-03-12 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Voting Rights Announcements' and explicitly states 'Notification of Major Holdings' under German Securities Trading Act (WpHG). It details changes in the percentage of voting rights held by an individual (Jürgen Krebs) in aap Implantate AG, crossing a threshold on 07 Jan 2019. This directly corresponds to the definition of a Major Shareholding Notification, which tracks changes in significant ownership levels. This fits the definition for Major Shareholding Notification (MRQ) much better than general Regulatory Filings (RNS) or Director's Dealing (DIRS), as it specifically concerns the percentage of voting rights held by a shareholder.
2019-01-11 English
Antibacterial silver coating technology: Application for approval of human clinical study submitted to Federal Institute for Drugs and Medical Devices (BfArM)
Regulatory Filings Classification · 100% confidence The document is a news release dated December 19, 2018, announcing that aap Implantate AG submitted an application for approval of a human clinical study for its antibacterial silver coating technology to the Federal Institute for Drugs and Medical Devices (BfArM). This is a specific, material operational update concerning regulatory interaction and product development milestones, rather than a comprehensive financial report (like 10-K or IR), a management change (MANG), or a dividend announcement (DIV). It is a general corporate announcement disseminated via DGAP, which often falls under Regulatory Filings (RNS) if no other specific category fits. Since it details a specific regulatory step (submission for clinical study approval) which is crucial for future market approval, it is best classified as a general Regulatory Filing/Announcement, as it doesn't fit the definitions for LTR (Legal Proceedings), ER (Earnings Release), or CAP (Financing Update). RNS is the most appropriate fallback for significant, non-financial regulatory/operational news releases.
2018-12-19 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.